Ignite Creation Date:
2024-05-05 @ 5:16 PM
Last Modification Date:
2024-10-26 @ 9:30 AM
Study NCT ID:
NCT00420888
Status:
COMPLETED
Last Update Posted:
2015-07-22
First Post:
2007-01-09
Brief Title:
ABR-217620Naptumomab Estafenatox With Interferon-alpha IFN-alpha Compared to IFN-alpha Alone in Patients With Advanced Renal Cell Carcinoma
Sponsor:
Active Biotech AB
Organization:
Active Biotech AB
Study Overview
Official Title:
A Randomized Open-label Multi-center Phase IIIII Study on Treatment With ABR-217620Naptumomab Estafenatox Combined With IFN-alpha vs IFN-alpha Alone in Patients With Advanced Renal Cell Carcinoma
Status:
COMPLETED
Status Verified Date:
2014-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The drug ABR-217620naptumomab estafenatox is a fusion of two proteins one that recognizes tumor cells and one that triggers an attack on the tumor cells by activating some white blood cells belonging to the bodys normal immune system This results in an accumulation of white blood cells in the cancer that can fight the cancer This study will compare the safety and effectiveness assessed by tumor status and survival of ABR-217620naptumomab estafenatox when given with standard therapy IFN-alpha to IFN-alpha alone in patients with advanced renal cell carcinoma RCC
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None